Naito Koma, Oura Shoji, Yoshimasu Tatsuya, Nakamura Rie, Hirai Yoshimitsu, Kiyoi Megumi, Miyasaka Miwako, Okamura Yoshitaka
Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University.
Gan To Kagaku Ryoho. 2010 Oct;37(10):1913-6.
To evaluate the feasibility of adjuvant docetaxel plus cyclophosphamide(TC)therapy for breast cancer.
A total of 16 patients with intermediate risk-breast cancer were enrolled. TC therapy consisted of four courses of docetaxel 75 mg/m² plus cyclophosphamide 600 mg/m² intravenous administration over three weeks. Every infusion was premedicated with intravenous administration of granisetron 3 mg plus dexamethasone 16 mg, followed by dexamethasone 8 mg p. o. on days 2 and 3.
Due to the allergic reaction, one patient discontinued TC therapy. Fifteen (94%) of the 16 patients completed the scheduled TC therapy. Feasibility was 93.7%. Grade 3/4 toxicity was limited to leucopenia, neutropenia, and febrile neutropenia. No non-hematological serious adverse events were observed.
Adjuvant TC therapy is a feasible option for breast cancer.
